Computational design of novel chimeric multiepitope vaccine against bacterial and viral disease in tilapia (Oreochromis sp.)

• Published in: Scientific reports Vol. 14; no. 1; pp. 14048 - 14
• Main Authors: Pumchan, Ansaya, Proespraiwong, Porranee, Sawatdichaikul, Orathai, Phurahong, Thararat, Hirono, Ikuo, Unajak, Sasimanas
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18.06.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114; 631/337; 631/45; 631/61; Allergenicity; Amino acids; Animals; Antigenicity; Antigens; Bacterial disease; Bacterial Infections - immunology; Bacterial Infections - prevention & control; Bacterial Vaccines - immunology; Chimeric multiepitope vaccine (CMEV); Cloning; Design; Disease prevention; Epitopes; Epitopes - immunology; Epitopes, B-Lymphocyte - immunology; Fish diseases; Fish Diseases - immunology; Fish Diseases - prevention & control; Fish Diseases - virology; Fish vaccine; Glycosylation; Humanities and Social Sciences; Immune response; Infectious diseases; Lymphocytes B; Molecular Docking Simulation; Molecular weight; multidisciplinary; Prevention; Proteins; Science; Science (multidisciplinary); Structural vaccine design; Tilapia - immunology; Vaccines; Viral diseases; Viral Vaccines - immunology; Virus Diseases - immunology; Virus Diseases - prevention & control; Fish diseases; Fish vaccine; Chimeric multiepitope vaccine (CMEV); Structural vaccine design; Bacterial disease
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-64383-z

Regarding several infectious diseases in fish, multiple vaccinations are not favorable. The chimeric multiepitope vaccine (CMEV) harboring several antigens for multi-disease prevention would enhance vaccine efficiency in terms of multiple disease prevention. Herein, the immunogens of tilapia’s seven pathogens including E. tarda , F. columnare , F. noatunensis , S. iniae , S. agalactiae , A. hydrophila, and TiLV were used for CMEV design. After shuffling and annotating the B-cell epitopes, 5,040 CMEV primary protein structures were obtained. Secondary and tertiary protein structures were predicted by AlphaFold2 creating 25,200 CMEV. Proper amino acid alignment in the secondary structures was achieved by the Ramachandran plot. In silico determination of physiochemical and other properties including allergenicity, antigenicity, glycosylation, and conformational B-cell epitopes were determined. The selected CMEV (OSLM0467, OSLM2629, and OSLM4294) showed a predicted molecular weight (MW) of 70 kDa, with feasible sites of N- and O- glycosylation, and a number of potentially conformational B-cell epitope residues. Molecular docking, codon optimization, and in-silico cloning were tested to evaluate the possibility of protein expression. Those CMEVs will further elucidate in vitro and in vivo to evaluate the efficacy and specific immune response. This research will highlight the new era of vaccines designed based on in silico structural vaccine design.